Home > Pressrelease > Fabry Disease Treatment Market size to exceed $3.5bn by 2030

Fabry Disease Treatment Market size to exceed $3.5bn by 2030

  • Published Date: September 26, 2022

Fabry Disease Treatment Market size is anticipated to surpass USD 3.5 billion by 2030, as per a new research report announced by Global Market Insights Inc.

Rising awareness about early disease detection will be a prominent factor fostering the market development. In recent years, disease treatment outcomes have significantly improved, due to the increasing knowledge of early therapy among physicians and specialists. Varied initiatives to improve awareness and research activities associated with the disease have also been launched.

Rising improvements in chaperone therapy to support industry development

Chaperone therapy segment is projected to cross USD 980 million by 2030. This can be credited to the constant improvements in the treatment, along with the high success rate. Varied research and development activities pertaining to the development of highly efficient therapies are being conducted, as per the report. This increasing availability of efficient Fabry disease treatment options is set to fuel segment progress.

Browse key industry insights spread across 109 pages with 123 market data tables & 17 figures & charts from the report, “Fabry Disease Treatment Market Size By Treatment Type (Enzyme Replacement Therapy (ERT) {By Drug Type (Agalsidase Alpha, Agalsidase Beta}, By End-use (Physician Office and Home Settings)}, Chaperone Therapy), By Industry Analysis Report, Price Trends, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2022 – 2030” in detail along with the table of contents:

Growing awareness about early disease diagnosis to drive the Europe industry demand

Europe Fabry disease treatment market is predicted to reach USD 1 billion by 2030. This is owing to the high awareness regarding the benefits of early-stage disease diagnosis and the extensive advantages offered by Fabry disease therapy. The burden of Fabry disease has also increased in the region, the report cites. According to a survey conducted in Germany, the disease is estimated to impact 1 to 5 per 10,000 persons. The growing prevalence of target diseases such as these will thus add impetus to the regional market growth.

Rapid product range development by key players to define the industry landscape

Some of the key players profiled in the report include JCR Pharmaceuticals Co Ltd., Takeda, Amicus Therapeutics, Sanofi, ISU Abaxis, and others.

The competitive landscape of the market is set to witness a series of disease treatment expansion initiatives among industry players. For instance, in July 2019, Takeda unveiled the Replagal (Agalsidase alfa), a recombinant human α-galactosidase A, in India. This was designed as an enzyme replacement therapy for Fabry disease. This product launch initiative will help the company to expand its market reach in the region.

Authors: Sumant Ugalmugle, Rupali Swain